Answers are grounded in this paper and cite their sources.
Review demonstrates the role of Janus kinase inhibitors in juvenile idiopathic arthritis, highlighting their utility for treatment-resistant joint and extraarticular complications.
Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of inflammatory arthritides encompassing at least six different categories, each with distinct clinical and biological characteristics. Despite significant advancements in the treatment of JIA, many cases of arthritis and/ or associated comorbidities such as chronic uveitis and interstitial lung disease (ILD) are refractory to current therapies. Janus kinase (JAK) inhibitors (JAKi) are small molecules or target–specific Disease Modifying Anti Rheumatic Drugs (tsDMARDs) that selectively inhibit janus kinases (JAKs) and block the JAK – Signal Transducers and Activators (STAT) pathway and the down steam proinflammatory effects associated with its activation. Herein, we review JAKi approved for the treatment of JIA and comment on JAKi currently with off- label use, with special considerations for their use in JIA-associated extraarticular manifestations and complications.
No takes yet. Share an insight, caveat, or question.
Tryfonos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: